Human Vaccines & Immunotherapeutics最新文献_第2页

Reconsidering the inclusion of Ladapo's work in the meta-analysis: Validity concerns and implications. 重新考虑将拉达波的工作纳入荟萃分析：有效性问题及影响

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-15 DOI: 10.1080/21645515.2024.2315711

Borja Somovilla Del Saz

引用次数: 0

Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season. 德国和芬兰在 2022/23 流感季节加强对高剂量和标准剂量四价灭活分裂病毒流感疫苗的被动安全性监测。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-06 DOI: 10.1080/21645515.2024.2322196

Marina Amaral de Avila Machado, Sonja Gandhi-Banga, Sophie Gallo, Tathyana Giannotti Cousseau, Reddappa Maniganahally Byrareddy, Markku Nissilä, Jörg Schelling, Celine Monfredo

{"title":"Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the 2022/23 influenza season.","authors":"Marina Amaral de Avila Machado, Sonja Gandhi-Banga, Sophie Gallo, Tathyana Giannotti Cousseau, Reddappa Maniganahally Byrareddy, Markku Nissilä, Jörg Schelling, Celine Monfredo","doi":"10.1080/21645515.2024.2322196","DOIUrl":"10.1080/21645515.2024.2322196","url":null,"abstract":"Enhanced Passive Safety Surveillance (EPSS) was conducted for quadrivalent inactivated split-virion influenza vaccines (IIV4) in Germany (high dose [HD]) and Finland (standard dose [SD]) for the northern hemisphere (NH) 2022/23 influenza season. The primary objective was to assess adverse events following immunization (AEFI) occurring ≤7 days post-vaccination. In each country, the EPSS was conducted at the beginning of the NH influenza season. Exposure information was documented using vaccination cards (VC), and AEFI were reported via an electronic data collection system or telephone. AEFI were assessed by seriousness and age group (Finland only). The vaccinee reporting rate (RR) was calculated as the number of vaccinees reporting ≥ 1 AEFI divided by the total vaccinees. In Germany, among 1041 vaccinees, there were 31 AEFI (ten vaccinees) during follow-up, including one serious AEFI. Of 16 AEFI (six vaccinees) with reported time of onset, 15 occurred ≤7 days post-vaccination (RR 0.58%, 95% confidence interval [CI] 0.21, 1.25), which was lower than the 2021/22 season (RR 1.88%, 95% CI: 1.10, 3.00). In Finland, among 1001 vaccinees, there were 142 AEFI (51 vaccinees) during follow-up, none of which were serious. Of 133 AEFI (48 vaccinees) with time of onset reported, all occurred ≤7 days post-vaccination (RR 4.80%, 95% CI: 3.56, 6.31), which was similar to the 2021/22 season (RR 4.90%, 95% CI: 3.65, 6.43). The EPSS for HD-IIV4 and for SD-IIV4 in the 2022/23 influenza season did not suggest any clinically relevant changes in safety beyond what is known/expected for IIV4s.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2322196"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10936612/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140050775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR). 一项 3 期、单臂、开放标签研究，旨在评估 15 价肺炎球菌结合疫苗 V114 在韩国健康婴儿中采用 3+1 方案的安全性、耐受性和免疫原性 (PNEU-PED-KOR)。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-18 DOI: 10.1080/21645515.2024.2321035

Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi Lucy Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, Natalie Banniettis

{"title":"A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR).","authors":"Alvino Maestri, Su Eun Park, Fiona Fernandes, Zhongyi Lucy Li, Yae-Jean Kim, Yun-Kyung Kim, Jin Lee, Ji Young Park, Dong Hyun Kim, GyongSeon Yang, Hyunjung Lim, Jin Oh Kim, Robert Lupinacci, Tina M Sterling, Marissa Wilck, Alejandra Esteves-Jaramillo, Natalie Banniettis","doi":"10.1080/21645515.2024.2321035","DOIUrl":"10.1080/21645515.2024.2321035","url":null,"abstract":"There is an ongoing burden of pneumococcal disease in children despite the use of pneumococcal conjugate vaccines (PCVs). This phase 3, open-label, single-arm, multisite, descriptive study was designed to evaluate the safety and immunogenicity of a 3 + 1 regimen of V114 (VAXNEUVANCE™), a 15-valent PCV, in South Korean infants and toddlers. Adverse events (AEs) were reported for 14 d following any vaccination, and throughout the study period for serious AEs. Serotype-specific immunoglobulin G (IgG) response rates (proportion of participants meeting an IgG threshold value of ≥0.35 μg/mL) and geometric mean concentrations (GMCs) for the 15 serotypes at 30 d postdose 3 (PD3) and at 30 d postdose 4 (PD4) were evaluated as endpoints. Healthy infants enrolled at 42-90 d after birth were vaccinated with V114 (N = 57). The most commonly reported AEs were those solicited in the trial. The majority of reported AEs were transient and of mild or moderate intensity. Few serious AEs were reported; none were vaccine related. No participants died nor discontinued the study vaccine because of an AE. V114 was immunogenic for all 15 serotypes contained in the vaccine, as assessed by IgG response rates at 30 d PD3 and IgG GMCs at 30 d PD3 and at 30 d PD4. V114 was well tolerated and immunogenic when administered as a 3 + 1 regimen in healthy South Korean infants and toddlers.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2321035"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10950266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 更正。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-07-16 DOI: 10.1080/21645515.2024.2379689

引用次数: 0

Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis. 细胞疫苗作为癌症疗法的效用：系统回顾和荟萃分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-27 DOI: 10.1080/21645515.2024.2323256

Ankur Tiwari, Karl Alcover, Elizabeth Carpenter, Katryna Thomas, Julia Krum, Alexander Nissen, Spencer Van Decar, Todd Smolinsky, Franklin Valdera, Timothy Vreeland, Markus Lacher, Giuseppe Del Priore, William Williams, Alexander Stojadinovic, George Peoples, Guy Clifton

{"title":"Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis.","authors":"Ankur Tiwari, Karl Alcover, Elizabeth Carpenter, Katryna Thomas, Julia Krum, Alexander Nissen, Spencer Van Decar, Todd Smolinsky, Franklin Valdera, Timothy Vreeland, Markus Lacher, Giuseppe Del Priore, William Williams, Alexander Stojadinovic, George Peoples, Guy Clifton","doi":"10.1080/21645515.2024.2323256","DOIUrl":"10.1080/21645515.2024.2323256","url":null,"abstract":"Cell-based therapeutic cancer vaccines use autologous patient-derived tumor cells, allogeneic cancer cell lines or autologous antigen presenting cells to mimic the natural immune process and stimulate an adaptive immune response against tumor antigens. The primary objective of this study is to perform a systematic literature review with an embedded meta-analysis of all published Phase 2 and 3 clinical trials of cell-based cancer vaccines in human subjects. The secondary objective of this study is to review trials demonstrating biological activity of cell-based cancer vaccines that could uncover additional hypotheses, which could be used in the design of future studies. We performed the systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The final review included 36 studies - 16 single-arm studies, and 20 controlled trials. Our systematic review of the existing literature revealed largely negative trials and our meta-analysis did not show evidence of clinical benefit from cell-based cancer-vaccines. However, as we looked beyond the stringent inclusion criteria of our systematic review, we identified significant examples of biological activity of cell-based cancer vaccines that are worth highlighting. In conclusion, the existing literature on cell-based cancer vaccines is highly variable in terms of cancer type, vaccine therapies and the clinical setting with no overall statistically significant clinical benefit, but there are individual successes that represent the promise of this approach. As cell-based vaccine technology continues to evolve, future studies can perhaps fulfill the potential that this exciting field of anti-cancer therapy holds.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2323256"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10984131/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140307553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020). 西班牙与肛门和阴茎肿瘤相关的住院负担（2016-2020 年）。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-04-01 DOI: 10.1080/21645515.2024.2334001

Victor Fernandez-Alonso, Ruth Gil-Prieto, Maria Amado-Anton-Pacheco, Valentín Hernández-Barrera, Ángel Gil-De-Miguel

{"title":"Hospitalization burden associated with anus and penis neoplasm in Spain (2016-2020).","authors":"Victor Fernandez-Alonso, Ruth Gil-Prieto, Maria Amado-Anton-Pacheco, Valentín Hernández-Barrera, Ángel Gil-De-Miguel","doi":"10.1080/21645515.2024.2334001","DOIUrl":"10.1080/21645515.2024.2334001","url":null,"abstract":"In 2020, there were approximately 50,865 anal cancer cases and 36,068 penile cancer cases worldwide. HPV is considered the main causal agent for the development of anal cancer and one of the causal agents responsible for the development of penile cancer. The aim of this epidemiological, descriptive, retrospective study was to describe the burden of hospitalization associated with anal neoplasms in men and women and with penis neoplasms in men in Spain from 2016 to 2020. The National Hospital Data Surveillance System of the Ministry of Health, Conjunto Mínimo Básico de Datos, provided the discharge information used in this observational retrospective analysis. A total of 3,542 hospitalizations due to anal cancer and 4,270 hospitalizations due to penile cancer were found; For anal cancer, 57.4% of the hospitalizations occurred in men, and these hospitalizations were also associated with significantly younger mean age, longer hospital stays and greater costs than those in women. HIV was diagnosed in 11.19% of the patients with anal cancer and 1.74% of the patients with penile cancer. The hospitalization rate was 2.07 for men and 1.45 for women per 100,000 in anal cancer and of 4.38 per 100,000 men in penile cancer. The mortality rate was 0.21 for men and 0.12 for women per 100,000 in anal cancer and 0.31 per 100.000 men in penile cancer and the case-fatality rate was 10.07% in men and 8,26% in women for anal cancer and 7.04% in penile cancer. HIV diagnosis significantly increased the cost of hospitalization. For all the studied diagnoses, the median length of hospital stays and hospitalization cost increased with age. Our study offers relevant data on the burden of hospitalization for anal and penile cancer in Spain. This information can be useful for future assessment on the impact of preventive measures, such as screening or vaccination in Spain.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2334001"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis. 抗PD-1/PDL-1和抗CTLA-4疗法中的免疫调节和肿瘤微环境对癌症免疫逃避的影响：文献计量分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-02-28 DOI: 10.1080/21645515.2024.2318815

Yi Huang, Zhijian Chen, Gang Shen, Shuogui Fang, Junjiong Zheng, Zepai Chi, Yuanfeng Zhang, Yitong Zou, Qinghua Gan, Chengxiao Liao, Yuhui Yao, Jianqiu Kong, Xinxiang Fan

{"title":"Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis.","authors":"Yi Huang, Zhijian Chen, Gang Shen, Shuogui Fang, Junjiong Zheng, Zepai Chi, Yuanfeng Zhang, Yitong Zou, Qinghua Gan, Chengxiao Liao, Yuhui Yao, Jianqiu Kong, Xinxiang Fan","doi":"10.1080/21645515.2024.2318815","DOIUrl":"10.1080/21645515.2024.2318815","url":null,"abstract":"This study aims to conduct a bibliometric analysis, employing visualization tools to examine literature pertaining to tumor immune evasion related to anti-CTLA-4 and anti-PD-1/PD-L1 therapy from 1999 to 2022. A special emphasis is placed on the interplay between tumor microenvironment, signaling pathways, immune cells and immune evasion, with data sourced from the Web of Science core collection (WoSCC). Advanced tools, including VOSviewer, Citespace, and Scimago Graphica, were utilized to analyze various parameters, such as co-authorship/co-citation patterns, regional contributions, journal preferences, keyword co-occurrences, and significant citation bursts. Out of 4778 publications reviewed, there was a marked increase in research focusing on immune evasion, with bladder cancer being notably prominent. Geographically, China, the USA, and Japan were the leading contributors. Prestigious institutions like MD Anderson Cancer Center, Harvard Medical School, Fudan University, and Sun Yat Sen University emerged as major players. Renowned journals in this domain included Frontiers in Immunology, Cancers, and Frontiers in Oncology. Ehen LP and Wang W were identified as prolific authors on this topic, while Topalian SL stood out as one of the most cited. Research current situation is notably pivoting toward challenges like immunotherapy resistance and the intricate signaling pathways driving drug resistance. This bibliometric study seeks to provide a comprehensive overview of past and current research trends, emphasizing the potential role of tumor microenvironment, signaling pathways and immune cells in the context of immune checkpoint inhibitors (ICIs) and tumor immune evasion.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2318815"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human papillomavirus vaccination uptake and determinant factors among adolescent schoolgirls in sub-Saharan Africa: A systematic review and meta-analysis. 撒哈拉以南非洲女学生接种人类乳头瘤病毒疫苗的情况及其决定因素：系统回顾和荟萃分析。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-20 DOI: 10.1080/21645515.2024.2326295

Yordanos Sisay Asgedom, Tsegaye Melaku Kebede, Beminate Lemma Seifu, Kusse Urmale Mare, Zufan Alamrie Asmare, Hiwot Altaye Asebe, Bizunesh Fantahun Kase, Abdu Hailu Shibeshi, Tsion Mulat Tebeje, Kebede Gemeda Sabo, Bezawit Melak Fente, Afework Alemu Lombebo, Mengistu Meskele Koyira, Gizachew Ambaw Kassie

{"title":"Human papillomavirus vaccination uptake and determinant factors among adolescent schoolgirls in sub-Saharan Africa: A systematic review and meta-analysis.","authors":"Yordanos Sisay Asgedom, Tsegaye Melaku Kebede, Beminate Lemma Seifu, Kusse Urmale Mare, Zufan Alamrie Asmare, Hiwot Altaye Asebe, Bizunesh Fantahun Kase, Abdu Hailu Shibeshi, Tsion Mulat Tebeje, Kebede Gemeda Sabo, Bezawit Melak Fente, Afework Alemu Lombebo, Mengistu Meskele Koyira, Gizachew Ambaw Kassie","doi":"10.1080/21645515.2024.2326295","DOIUrl":"10.1080/21645515.2024.2326295","url":null,"abstract":"Despite the ongoing global vaccination campaign aimed at preventing human papillomavirus (HPV) related health issues, the uptake of the HPV vaccine remains unacceptably low in developing regions, particularly in sub-Saharan Africa (SSA). Therefore, this systematic review and meta-analysis aimed at determining the pooled prevalence and associated factors of HPV vaccine uptake among adolescent school girls in SSA. Electronic bio-medical databases were explored. Pooled prevalence, publication bias, meta-regression, sub-group, and sensitivity analysis were performed. The estimated pooled prevalence of HPV vaccine uptake was 28.53% [95% CI: (5.25, 51.81)]. Having good knowledge and a positive attitude was significantly associated with HPV vaccine uptake in SSA. Subgroup analysis revealed the highest uptake was 62.52% from Kenya and the lowest was 3.77% in Nigeria. The HPV vaccine uptake is low. It underscores the need for community education, school-based immunization, and education programs that promote the uptake of the vaccine to increase coverage.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2326295"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10956624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140177310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan. COVID-19 疫苗接种情况对住院和疾病严重程度的影响：日本长崎县的一项描述性研究。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-22 DOI: 10.1080/21645515.2024.2322795

Guoxi Cai, Shiwen Liu, Yixiao Lu, Yumika Takaki, Fumiaki Matsumoto, Akira Yoshikawa, Toshitsugu Taguri, Jianfen Xie, Kazuhiko Arima, Satoshi Mizukami, Jiwen Wu, Taro Yamamoto, Maiko Hasegawa, Nguyen Tien Huy, Masaya Saito, Shouhei Takeuchi, Kouichi Morita, Kiyoshi Aoyagi, Fei He

{"title":"Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan.","authors":"Guoxi Cai, Shiwen Liu, Yixiao Lu, Yumika Takaki, Fumiaki Matsumoto, Akira Yoshikawa, Toshitsugu Taguri, Jianfen Xie, Kazuhiko Arima, Satoshi Mizukami, Jiwen Wu, Taro Yamamoto, Maiko Hasegawa, Nguyen Tien Huy, Masaya Saito, Shouhei Takeuchi, Kouichi Morita, Kiyoshi Aoyagi, Fei He","doi":"10.1080/21645515.2024.2322795","DOIUrl":"10.1080/21645515.2024.2322795","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) was extraordinarily harmful, with high rates of infection and hospitalization. This study aimed to evaluate the impact of COVID-19 vaccination status and other factors on hospitalization and disease severity, using data from Nagasaki Prefecture, Japan. Confirmed cases of COVID-19 infection with vaccination status were included and the differences in characteristics between different vaccination statuses, hospitalization or not, and patients with varying levels of disease severity were analyzed. Furthermore, logistic regression was used to calculate odds ratio (ORs) and 95% confidence intervals (CI) to evaluate the association of various factors with hospitalization and disease severity. From March 14, 2020 to August 31, 2022, 23,139 patients were unvaccinated 13,668 vaccinated the primary program with one or two doses, and 4,575 completed the booster. Vaccination reduced the risk of hospitalization with an odd ratio of 0.759 (95% CI: 0.654-0.881) and the protective effect of completed booster vaccination was more pronounced (OR: 0.261, 95% CI: 0.207-0.328). Similarly, vaccination significantly reduced the risk of disease severity (vaccinated primary program: OR: 0.191, 95% CI: 0.160-0.228; completed booster vaccination: OR: 0.129, 95% CI: 0.099-0.169). Overall, unvaccinated, male, elderly, immunocompromised, obese, and patients with other severe illness factors were all risk factors for COVID-19-related hospitalization and disease severity. Vaccination was associated with a decreased risk of hospitalization and disease severity, and highlighted the benefits of completing booster.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2322795"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Opportunities for HPV vaccine education in school-based immunization programs in British Columbia, Canada: A qualitative study. 加拿大不列颠哥伦比亚省校本免疫计划中的 HPV 疫苗教育机会：定性研究。

IF 4.1 4区医学

Human Vaccines & Immunotherapeutics Pub Date : 2024-12-31 Epub Date: 2024-03-22 DOI: 10.1080/21645515.2024.2326779

Isabella Brohman, Gabriel Blank, Hana Mitchell, Eve Dubé, Julie A Bettinger

{"title":"Opportunities for HPV vaccine education in school-based immunization programs in British Columbia, Canada: A qualitative study.","authors":"Isabella Brohman, Gabriel Blank, Hana Mitchell, Eve Dubé, Julie A Bettinger","doi":"10.1080/21645515.2024.2326779","DOIUrl":"10.1080/21645515.2024.2326779","url":null,"abstract":"Despite the availability of school-based immunization programs (SBIPs) in Canada, human papillomavirus (HPV) vaccine uptake remains suboptimal. Vaccine education may improve vaccine uptake among adolescents. The objective of this qualitative study was to identify opportunities for HPV vaccine education in British Columbia, Canada, by exploring the perspectives of students, parents, school staff, and public health nurses on the current SBIP. Individual semi-structured interviews were conducted with adult participants and focus groups were conducted with grade 6 students between November 2019 and May 2020. The interviews and focus groups were transcribed and then analyzed using reflexive thematic analysis. Opportunities for HPV vaccine education were identified in three themes: 1) making SBIPs student-centered; 2) adopting a collaborative and interdisciplinary approach to vaccine education; and 3) actualizing parent education opportunities. Broad support existed for a formal, collaborative HPV grade 6 vaccine curriculum delivered by teachers and public health nurses to provide evidence-based health information. Participants voiced that the curriculum should integrate students' perspectives on topics of interest and address needle associated pain and anxiety. Parents were identified as the primary vaccine decisionmakers, therefore, participants stated it was crucial to also provide parent-directed vaccine education as part of SBIP. Our findings support the development of a collaborative HPV vaccine curriculum directed to and informed by students and parents to buttress current SBIPs in British Columbia.","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"20 1","pages":"2326779"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140186148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0